Symbols / ABBV Stock $208.50 +0.31% AbbVie Inc.

Healthcare • Drug Manufacturers - General • United States • NYQ
ABBV (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - General
CEO —
Exch · Country NYQ · United States
Market Cap 368.38B
Enterprise Value 430.81B
Income 3.60B
Sales 62.82B
FCF (ttm) 20.81B
Book/sh -3.77
Cash/sh 5.32
Employees 57,000
Insider 10d —
IPO Jan 02, 2013
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 3.26%
P/E 102.21
Forward P/E 12.86
PEG 0.57
P/S 5.86
P/B -55.35
P/C —
EV/EBITDA 14.40
EV/Sales 6.86
Quick Ratio 0.52
Current Ratio 0.80
Debt/Eq —
LT Debt/Eq —
EPS (ttm) 2.04
EPS next Y 16.21
EPS Growth -46.20%
Revenue Growth 12.40%
EPS Gr Q/Q -46.00%
Rev Gr Q/Q —
Earnings (next) 2026-07-30
Earnings (prior) 2026-04-29
ROA 10.03%
ROE —
ROIC —
Gross Margin 72.03%
Oper. Margin 32.16%
Profit Margin 5.79%
Shs Outstand 1.77B
Shs Float 1.76B
Insider Own 0.11%
Instit Own 77.48%
Short Float 1.37%
Short Ratio 3.06
Short Interest 21.85M
52W High 244.81
vs 52W High -14.83%
52W Low 176.57
vs 52W Low 18.08%
Beta 0.30
Impl. Vol. 29.90%
Rel Volume 0.81
Avg Volume 6.84M
Volume 5.53M
Target (mean) $252.23
Tgt Median $253.50
Tgt Low $184.00
Tgt High $328.00
# Analysts 30
Recom Buy
Prev Close $207.86
Price $208.50
Change 0.31%
About

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$252.23
Mean price target
2. Current target
$208.50
Latest analyst target
3. DCF / Fair value
$212.03
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$208.50
Low
$184.00
High
$328.00
Mean
$252.23

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-04 main Evercore ISI Group Outperform → Outperform $236
2026-05-01 reit Guggenheim Buy → Buy $249
2026-04-30 main Canaccord Genuity Buy → Buy $265
2026-04-30 main Morgan Stanley Overweight → Overweight $278
2026-04-30 reit Cantor Fitzgerald Overweight → Overweight $240
2026-04-23 main Piper Sandler Overweight → Overweight $294
2026-04-21 init Canaccord Genuity — → Buy $262
2026-04-10 main Guggenheim Buy → Buy $249
2026-04-08 main Cantor Fitzgerald Overweight → Overweight $240
2026-02-25 init RBC Capital — → Outperform $260
2026-02-20 init Barclays — → Overweight $275
2026-02-18 main Piper Sandler Overweight → Overweight $299
2026-02-17 main Freedom Broker Buy → Buy $260
2026-02-05 main UBS Neutral → Neutral $230
2026-02-05 main Evercore ISI Group Outperform → Outperform $228
2026-02-05 main Morgan Stanley Overweight → Overweight $270
2026-01-27 main Citigroup Neutral → Neutral $230
2026-01-08 down Wolfe Research Outperform → Peer Perform —
2025-12-12 main Morgan Stanley Overweight → Overweight $269
2025-12-10 up HSBC Hold → Buy $265
News
RSS: Latest ABBV news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-04 PURDUE DAVID R. Officer — 5,230 $233.56 $1,221,519
2026-03-02 SIATIS PERRY C. General Counsel — 18,668 $233.51 $4,375,549
2026-02-25 SIATIS PERRY C. General Counsel — 22,381 $149.62 $3,863,458
2026-02-25 SIATIS PERRY C. General Counsel — 22,381 $230.00 $5,147,630
2026-02-18 REENTS SCOTT T. Chief Financial Officer — 48,838 $0.00 $0
2026-02-18 SIATIS PERRY C. General Counsel — 33,518 $0.00 $0
2026-02-18 THAKKAR ROOPAL Officer — 18,137 $0.00 $0
2026-02-18 PURDUE DAVID R. Officer — 6,071 $0.00 $0
2026-02-18 CRUM DEMETRIS D Officer — 2,460 $0.00 $0
2026-02-18 SALEKI-GERHARDT AZITA Chief Operating Officer — 36,811 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
61,160.00
+8.57%
56,334.00
+3.71%
54,318.00
-6.44%
58,054.00
Operating Revenue
61,160.00
+8.57%
56,334.00
+3.71%
54,318.00
-6.44%
58,054.00
Cost Of Revenue
18,204.00
+7.69%
16,904.00
-17.20%
20,415.00
+17.23%
17,414.00
Reconciled Cost Of Revenue
18,204.00
+7.69%
16,904.00
-17.20%
20,415.00
+17.23%
17,414.00
Gross Profit
42,956.00
+8.94%
39,430.00
+16.30%
33,903.00
-16.58%
40,640.00
Operating Expense
22,865.00
-16.96%
27,536.00
+35.19%
20,368.00
-6.68%
21,826.00
Research And Development
9,096.00
-28.89%
12,791.00
+66.66%
7,675.00
+17.90%
6,510.00
Selling General And Administration
14,010.00
-5.03%
14,752.00
+14.61%
12,872.00
-15.65%
15,260.00
Other Operating Expenses
-241.00
-3342.86%
-7.00
+96.09%
-179.00
-419.64%
56.00
Total Expenses
41,069.00
-7.59%
44,440.00
+8.97%
40,783.00
+3.93%
39,240.00
Operating Income
20,091.00
+68.92%
11,894.00
-12.12%
13,535.00
-28.06%
18,814.00
Total Operating Income As Reported
15,075.00
+64.99%
9,137.00
-28.38%
12,757.00
-29.59%
18,117.00
EBITDA
17,629.00
+18.24%
14,910.00
-13.17%
17,172.00
-28.97%
24,174.00
Normalized EBITDA
22,703.00
+28.35%
17,688.00
-2.25%
18,096.00
-27.67%
25,019.00
Reconciled Depreciation
8,139.00
-2.95%
8,386.00
-3.59%
8,698.00
+2.73%
8,467.00
EBIT
9,490.00
+45.46%
6,524.00
-23.01%
8,474.00
-46.05%
15,707.00
Total Unusual Items
-5,074.00
-82.65%
-2,778.00
-200.65%
-924.00
-9.35%
-845.00
Total Unusual Items Excluding Goodwill
-5,074.00
-82.65%
-2,778.00
-200.65%
-924.00
-9.35%
-845.00
Special Income Charges
-5,016.00
-81.94%
-2,757.00
-254.37%
-778.00
-11.62%
-697.00
Other Special Charges
5,016.00
+81.94%
2,757.00
+254.37%
778.00
+11.62%
697.00
Net Income
4,226.00
-1.22%
4,278.00
-12.03%
4,863.00
-58.91%
11,836.00
Pretax Income
6,597.00
+77.53%
3,716.00
-40.54%
6,250.00
-53.62%
13,477.00
Net Non Operating Interest Income Expense
-2,627.00
-21.62%
-2,160.00
-28.27%
-1,684.00
+17.61%
-2,044.00
Interest Expense Non Operating
2,893.00
+3.03%
2,808.00
+26.26%
2,224.00
-0.27%
2,230.00
Net Interest Income
-2,627.00
-21.62%
-2,160.00
-28.27%
-1,684.00
+17.61%
-2,044.00
Interest Expense
2,893.00
+3.03%
2,808.00
+26.26%
2,224.00
-0.27%
2,230.00
Interest Income Non Operating
266.00
-58.95%
648.00
+20.00%
540.00
+190.32%
186.00
Interest Income
266.00
-58.95%
648.00
+20.00%
540.00
+190.32%
186.00
Other Income Expense
-10,867.00
-80.57%
-6,018.00
-7.45%
-5,601.00
-70.09%
-3,293.00
Other Non Operating Income Expenses
-5,793.00
-78.80%
-3,240.00
+30.72%
-4,677.00
-91.05%
-2,448.00
Gain On Sale Of Security
-58.00
-176.19%
-21.00
+85.62%
-146.00
+1.35%
-148.00
Tax Provision
2,364.00
+514.74%
-570.00
-141.39%
1,377.00
-15.63%
1,632.00
Tax Rate For Calcs
0.00
+70.64%
0.00
-4.55%
0.00
+81.82%
0.00
Tax Effect Of Unusual Items
-1,818.24
-211.67%
-583.38
-186.98%
-203.28
-98.82%
-102.25
Net Income Including Noncontrolling Interests
4,233.00
-1.24%
4,286.00
-12.05%
4,873.00
-58.86%
11,845.00
Net Income From Continuing Operation Net Minority Interest
4,226.00
-1.22%
4,278.00
-12.03%
4,863.00
-58.91%
11,836.00
Net Income From Continuing And Discontinued Operation
4,226.00
-1.22%
4,278.00
-12.03%
4,863.00
-58.91%
11,836.00
Net Income Continuous Operations
4,233.00
-1.24%
4,286.00
-12.05%
4,873.00
-58.86%
11,845.00
Minority Interests
-7.00
+12.50%
-8.00
+20.00%
-10.00
-11.11%
-9.00
Normalized Income
7,481.76
+15.59%
6,472.62
+15.92%
5,583.72
-55.61%
12,578.75
Net Income Common Stockholders
4,186.00
-1.23%
4,238.00
-12.07%
4,820.00
-59.09%
11,782.00
Otherunder Preferred Stock Dividend
40.00
+0.00%
40.00
-6.98%
43.00
-20.37%
54.00
Diluted EPS
2.36
-1.26%
2.39
-12.13%
2.72
-58.97%
6.63
Basic EPS
2.39
-1.36%
2.42
-12.00%
2.75
-58.84%
6.69
Basic Average Shares
1,767.88
+0.15%
1,765.26
-0.04%
1,765.94
-0.18%
1,769.18
Diluted Average Shares
1,773.00
+0.00%
1,773.00
+0.00%
1,773.00
-0.28%
1,778.00
Diluted NI Availto Com Stockholders
4,186.00
-1.23%
4,238.00
-12.07%
4,820.00
-59.09%
11,782.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
133,960.00
-0.89%
135,161.00
+0.33%
134,711.00
-2.95%
138,805.00
Current Assets
29,062.00
+13.60%
25,582.00
-22.48%
33,002.00
+15.95%
28,463.00
Cash Cash Equivalents And Short Term Investments
5,257.00
-5.36%
5,555.00
-56.66%
12,816.00
+38.87%
9,229.00
Cash And Cash Equivalents
5,229.00
-5.34%
5,524.00
-56.89%
12,814.00
+39.27%
9,201.00
Other Short Term Investments
28.00
-9.68%
31.00
+1450.00%
2.00
-92.86%
28.00
Receivables
12,589.00
+15.29%
10,919.00
-2.12%
11,155.00
-0.88%
11,254.00
Accounts Receivable
12,589.00
+15.29%
10,919.00
-2.12%
11,155.00
-0.88%
11,254.00
Inventory
4,951.00
+18.42%
4,181.00
+2.00%
4,099.00
+14.53%
3,579.00
Raw Materials
1,084.00
+2.55%
1,057.00
-3.91%
1,100.00
+10.00%
1,000.00
Work In Process
2,287.00
+17.22%
1,951.00
+18.75%
1,643.00
+15.95%
1,417.00
Finished Goods
1,580.00
+34.70%
1,173.00
-13.50%
1,356.00
+16.70%
1,162.00
Prepaid Assets
—
—
—
—
Other Current Assets
6,265.00
+27.16%
4,927.00
-0.10%
4,932.00
+12.07%
4,401.00
Total Non Current Assets
104,898.00
-4.27%
109,579.00
+7.74%
101,709.00
-7.82%
110,342.00
Net PPE
5,628.00
+9.62%
5,134.00
+2.91%
4,989.00
+1.09%
4,935.00
Gross PPE
13,530.00
+10.30%
12,267.00
+5.43%
11,635.00
+5.91%
10,986.00
Accumulated Depreciation
-7,902.00
-10.78%
-7,133.00
-7.33%
-6,646.00
-9.83%
-6,051.00
Properties
0.00
0.00
0.00
0.00
Land And Improvements
287.00
+1.06%
284.00
-0.70%
286.00
+0.00%
286.00
Buildings And Improvements
3,057.00
+5.60%
2,895.00
+2.41%
2,827.00
+3.29%
2,737.00
Machinery Furniture Equipment
—
7,995.00
+7.33%
7,449.00
+4.81%
7,107.00
Construction In Progress
1,401.00
+28.18%
1,093.00
+1.86%
1,073.00
+25.35%
856.00
Other Properties
8,785.00
+9.88%
7,995.00
+7.33%
7,449.00
—
Goodwill And Other Intangible Assets
88,281.00
-7.10%
95,024.00
+8.10%
87,903.00
-11.74%
99,595.00
Goodwill
35,640.00
+1.96%
34,956.00
+8.25%
32,293.00
+0.43%
32,156.00
Other Intangible Assets
52,641.00
-12.36%
60,068.00
+8.02%
55,610.00
-17.54%
67,439.00
Investments And Advances
268.00
-3.94%
279.00
-8.22%
304.00
+26.14%
241.00
Other Non Current Assets
10,721.00
+17.27%
9,142.00
+7.39%
8,513.00
+52.81%
5,571.00
Total Liabilities Net Minority Interest
137,188.00
+4.09%
131,797.00
+6.02%
124,314.00
+2.30%
121,518.00
Current Liabilities
43,289.00
+11.72%
38,749.00
+2.40%
37,841.00
+28.11%
29,538.00
Payables And Accrued Expenses
34,734.00
+8.73%
31,945.00
+4.23%
30,650.00
+20.66%
25,402.00
Payables
6,691.00
+13.77%
5,881.00
-9.12%
6,471.00
+15.27%
5,614.00
Accounts Payable
3,592.00
+21.97%
2,945.00
-20.15%
3,688.00
+25.70%
2,934.00
Dividends Payable
3,099.00
+5.55%
2,936.00
+5.50%
2,783.00
+3.84%
2,680.00
Current Accrued Expenses
28,043.00
+7.59%
26,064.00
+7.80%
24,179.00
+22.19%
19,788.00
Employee Benefits
1,410.00
+14.26%
1,234.00
-19.77%
1,538.00
-6.11%
1,638.00
Current Debt And Capital Lease Obligation
8,555.00
+25.73%
6,804.00
-5.38%
7,191.00
+73.86%
4,136.00
Current Debt
8,555.00
+25.73%
6,804.00
-5.38%
7,191.00
+73.86%
4,136.00
Current Deferred Liabilities
—
14,304.00
+4.97%
13,627.00
+27.15%
10,717.00
Current Deferred Revenue
—
14,304.00
+4.97%
13,627.00
+27.15%
10,717.00
Total Non Current Liabilities Net Minority Interest
93,899.00
+0.91%
93,048.00
+7.60%
86,473.00
-5.99%
91,980.00
Long Term Debt And Capital Lease Obligation
58,941.00
-2.32%
60,340.00
+15.61%
52,194.00
-11.74%
59,135.00
Long Term Debt
58,941.00
-2.32%
60,340.00
+15.61%
52,194.00
-11.74%
59,135.00
Non Current Pension And Other Postretirement Benefit Plans
1,410.00
+14.26%
1,234.00
-19.77%
1,538.00
-6.11%
1,638.00
Tradeand Other Payables Non Current
364.00
-71.13%
1,261.00
-42.21%
2,182.00
-26.90%
2,985.00
Non Current Deferred Liabilities
2,389.00
-7.37%
2,579.00
+32.12%
1,952.00
-10.87%
2,190.00
Non Current Deferred Taxes Liabilities
2,389.00
-7.37%
2,579.00
+32.12%
1,952.00
-10.87%
2,190.00
Other Non Current Liabilities
30,795.00
+11.44%
27,634.00
-3.40%
28,607.00
+9.89%
26,032.00
Stockholders Equity
-3,270.00
-198.35%
3,325.00
-67.91%
10,360.00
-39.96%
17,254.00
Common Stock Equity
-3,270.00
-198.35%
3,325.00
-67.91%
10,360.00
-39.96%
17,254.00
Capital Stock
18.00
+0.00%
18.00
+0.00%
18.00
+0.00%
18.00
Common Stock
18.00
+0.00%
18.00
+0.00%
18.00
+0.00%
18.00
Share Issued
1,838.68
+0.39%
1,831.59
+0.47%
1,823.05
+0.51%
1,813.77
Ordinary Shares Number
1,767.88
+0.15%
1,765.26
-0.04%
1,765.94
-0.18%
1,769.18
Treasury Shares Number
70.80
+6.73%
66.34
+16.17%
57.11
+28.07%
44.59
Additional Paid In Capital
22,495.00
+5.45%
21,333.00
+5.71%
20,180.00
+4.86%
19,245.00
Retained Earnings
-15,493.00
-96.11%
-7,900.00
-690.00%
-1,000.00
-120.90%
4,784.00
Gains Losses Not Affecting Retained Earnings
-1,144.00
+40.57%
-1,925.00
+16.49%
-2,305.00
-4.82%
-2,199.00
Treasury Stock
9,146.00
+11.52%
8,201.00
+25.53%
6,533.00
+42.21%
4,594.00
Minority Interest
42.00
+7.69%
39.00
+5.41%
37.00
+12.12%
33.00
Other Equity Adjustments
-1,144.00
+40.57%
-1,925.00
+16.49%
-2,305.00
-4.82%
-2,199.00
Total Equity Gross Minority Interest
-3,228.00
-195.96%
3,364.00
-67.64%
10,397.00
-39.86%
17,287.00
Total Capitalization
55,671.00
-12.56%
63,665.00
+1.78%
62,554.00
-18.11%
76,389.00
Working Capital
-14,227.00
-8.05%
-13,167.00
-172.10%
-4,839.00
-350.14%
-1,075.00
Invested Capital
64,226.00
-8.86%
70,469.00
+1.04%
69,745.00
-13.39%
80,525.00
Total Debt
67,496.00
+0.52%
67,144.00
+13.07%
59,385.00
-6.14%
63,271.00
Net Debt
62,267.00
+1.05%
61,620.00
+32.31%
46,571.00
-13.87%
54,070.00
Net Tangible Assets
-91,551.00
+0.16%
-91,699.00
-18.26%
-77,543.00
+5.83%
-82,341.00
Tangible Book Value
-91,551.00
+0.16%
-91,699.00
-18.26%
-77,543.00
+5.83%
-82,341.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
19,030.00
+1.19%
18,806.00
-17.66%
22,839.00
-8.44%
24,943.00
Cash Flow From Continuing Operating Activities
19,030.00
+1.19%
18,806.00
-17.66%
22,839.00
-8.44%
24,943.00
Net Income From Continuing Operations
4,233.00
-1.24%
4,286.00
-12.05%
4,873.00
-58.86%
11,845.00
Depreciation Amortization Depletion
8,139.00
-2.95%
8,386.00
-3.59%
8,698.00
+2.73%
8,467.00
Depreciation
762.00
-0.26%
764.00
+1.60%
752.00
-3.34%
778.00
Amortization Cash Flow
7,377.00
-3.21%
7,622.00
-4.08%
7,946.00
+3.34%
7,689.00
Depreciation And Amortization
8,139.00
-2.95%
8,386.00
-3.59%
8,698.00
+2.73%
8,467.00
Amortization Of Intangibles
7,377.00
-3.21%
7,622.00
-4.08%
7,946.00
+3.34%
7,689.00
Other Non Cash Items
8,643.00
+93.36%
4,470.00
-7.09%
4,811.00
+53.02%
3,144.00
Stock Based Compensation
955.00
+4.83%
911.00
+21.95%
747.00
+11.33%
671.00
Provisionand Write Offof Assets
-933.00
-283.66%
508.00
+214.67%
-443.00
-119.75%
2,243.00
Asset Impairment Charge
847.00
-81.08%
4,476.00
+5.84%
4,229.00
+449.22%
770.00
Deferred Tax
-492.00
+66.05%
-1,449.00
+49.84%
-2,889.00
-49.61%
-1,931.00
Deferred Income Tax
-492.00
+66.05%
-1,449.00
+49.84%
-2,889.00
-49.61%
-1,931.00
Operating Gains Losses
—
—
—
-172.00
Change In Working Capital
-2,362.00
+15.10%
-2,782.00
-198.90%
2,813.00
+3092.55%
-94.00
Change In Receivables
-1,490.00
-819.81%
207.00
+213.64%
66.00
+104.54%
-1,455.00
Changes In Account Receivables
-1,490.00
-819.81%
207.00
+213.64%
66.00
+104.54%
-1,455.00
Change In Inventory
-234.00
+26.65%
-319.00
+23.50%
-417.00
+39.21%
-686.00
Change In Prepaid Assets
-827.00
-329.09%
361.00
+292.02%
-188.00
+28.79%
-264.00
Change In Payables And Accrued Expense
951.00
+437.29%
177.00
-95.39%
3,840.00
+117.07%
1,769.00
Change In Payable
951.00
+437.29%
177.00
-95.39%
3,840.00
+117.07%
1,769.00
Change In Account Payable
951.00
+437.29%
177.00
-95.39%
3,840.00
+117.07%
1,769.00
Change In Other Working Capital
-762.00
+76.25%
-3,208.00
-557.38%
-488.00
-190.04%
542.00
Investing Cash Flow
-6,643.00
+68.09%
-20,820.00
-936.34%
-2,009.00
-222.47%
-623.00
Cash Flow From Continuing Investing Activities
-6,643.00
+68.09%
-20,820.00
-936.34%
-2,009.00
-222.47%
-623.00
Net PPE Purchase And Sale
-1,214.00
-24.64%
-974.00
-25.35%
-777.00
-11.80%
-695.00
Purchase Of PPE
-1,214.00
-24.64%
-974.00
-25.35%
-777.00
-11.80%
-695.00
Capital Expenditure
-1,214.00
-24.64%
-974.00
-25.35%
-777.00
-11.80%
-695.00
Net Investment Purchase And Sale
41.00
-91.49%
482.00
+2290.91%
-22.00
-123.91%
92.00
Purchase Of Investment
-35.00
+52.05%
-73.00
+5.19%
-77.00
+94.65%
-1,438.00
Sale Of Investment
76.00
-86.31%
555.00
+909.09%
55.00
-96.41%
1,530.00
Net Business Purchase And Sale
-5,441.00
+73.48%
-20,517.00
-1577.60%
-1,223.00
-54.03%
-794.00
Purchase Of Business
-5,441.00
+73.48%
-20,517.00
-1577.60%
-1,223.00
-54.03%
-794.00
Gain Loss On Sale Of Business
—
0.00
0.00
+100.00%
-172.00
Net Other Investing Changes
-29.00
-115.34%
189.00
+1353.85%
13.00
-98.32%
774.00
Financing Cash Flow
-12,724.00
-144.18%
-5,211.00
+69.74%
-17,222.00
+30.56%
-24,803.00
Cash Flow From Continuing Financing Activities
-12,724.00
-144.18%
-5,211.00
+69.74%
-17,222.00
+30.56%
-24,803.00
Net Issuance Payments Of Debt
-304.00
-104.14%
7,350.00
+277.15%
-4,149.00
+66.63%
-12,433.00
Issuance Of Debt
9,291.00
-57.71%
21,971.00
0.00
-100.00%
2,000.00
Repayment Of Debt
-9,595.00
+34.38%
-14,621.00
-252.40%
-4,149.00
+71.25%
-14,433.00
Long Term Debt Issuance
3,994.00
-76.45%
16,963.00
0.00
-100.00%
2,000.00
Long Term Debt Payments
-6,797.00
+29.29%
-9,613.00
-131.69%
-4,149.00
+71.25%
-14,433.00
Net Long Term Debt Issuance
-2,803.00
-138.14%
7,350.00
+277.15%
-4,149.00
+66.63%
-12,433.00
Short Term Debt Issuance
5,297.00
+5.77%
5,008.00
0.00
0.00
Short Term Debt Payments
-2,798.00
+44.13%
-5,008.00
0.00
0.00
Net Short Term Debt Issuance
2,499.00
0.00
0.00
0.00
Net Common Stock Issuance
-980.00
+42.62%
-1,708.00
+13.39%
-1,972.00
-32.62%
-1,487.00
Common Stock Payments
-980.00
+42.62%
-1,708.00
+13.39%
-1,972.00
-32.62%
-1,487.00
Common Stock Dividend Paid
-11,657.00
-5.73%
-11,025.00
-4.61%
-10,539.00
-4.94%
-10,043.00
Cash Dividends Paid
-11,657.00
-5.73%
-11,025.00
-4.61%
-10,539.00
-4.94%
-10,043.00
Repurchase Of Capital Stock
-980.00
+42.62%
-1,708.00
+13.39%
-1,972.00
-32.62%
-1,487.00
Proceeds From Stock Option Exercised
172.00
-19.63%
214.00
+18.89%
180.00
-31.30%
262.00
Net Other Financing Charges
45.00
+207.14%
-42.00
+94.34%
-742.00
+32.67%
-1,102.00
Changes In Cash
-337.00
+95.34%
-7,225.00
-300.25%
3,608.00
+847.00%
-483.00
Effect Of Exchange Rate Changes
42.00
+164.62%
-65.00
-1400.00%
5.00
+108.06%
-62.00
Beginning Cash Position
5,524.00
-56.89%
12,814.00
+39.27%
9,201.00
-5.59%
9,746.00
End Cash Position
5,229.00
-5.34%
5,524.00
-56.89%
12,814.00
+39.27%
9,201.00
Free Cash Flow
17,816.00
-0.09%
17,832.00
-19.17%
22,062.00
-9.02%
24,248.00
Interest Paid Supplemental Data
3,002.00
+6.79%
2,811.00
+13.85%
2,469.00
-3.02%
2,546.00
Income Tax Paid Supplemental Data
3,626.00
-10.78%
4,064.00
-13.57%
4,702.00
+57.36%
2,988.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category